The proposed framework for so-called ‘march-in rights’ on taxpayer-funded drugs and other inventions is the latest entry in the US federal government’s playbook to limit price increases for drugs, and will no doubt throw it once again into open contention with the pharma industry.
If enacted, the policy would allow the government to license rights to manufacture medicines to other companies, provided they are prepared to make them available at “reasonable price.”
